GlassScriptPhysician profile
Roy S Lewis
NPI 1396728804
$17,618.13
in general payments reported to CMS, 2019-2025
30 companies · $881 in 2025
The $881 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $122 · 2021: $263 · 2022: $481 · 2023: $399 · 2024: $15K · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,534.90 |
| Food and Beverage | $2,690.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $13,920.74 | 2023-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Genzyme Corporation | $559.92 | 2019-2025 | |
| Inspire Medical Systems, INC. | $419.94 | 2022-2024 | Inspire |
| Alk-Abello, INC | $336.44 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Kaleo, INC. | $326.57 | 2019-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $316.81 | 2019-2025 | Dupixent, Eylea, Eylea Hd |
| Optinose US, INC. | $312.33 | 2019-2025 | |
| Acclarent, INC | $258.44 | 2019-2023 | Acclarent Aera |
| Integra Lifesciences Corporation | $179.74 | 2024 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Glaxosmithkline, LLC. | $170.89 | 2024-2025 | Nucala |
| Aerin Medical INC. | $133.88 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $97.39 | 2025 | Neffy |
| Stryker Corporation | $89.81 | 2019-2025 | Audion Et Dilation System |
| Astrazeneca Pharmaceuticals LP | $84.05 | 2019 | |
| Hikma Pharmaceuticals USA | $63.88 | 2023-2024 | Ryaltris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $48.96 | 2024-2025 | Tyrvaya, Ryzumvi |
| Medtronic, INC. | $36.45 | 2022-2025 | Propel |
| Paratek Pharmaceuticals, INC. | $33.61 | 2025 | Xhance |
| Harrow Eye, LLC | $27.99 | 2025 | Vevye |
| Intersect Ent, INC. | $24.75 | 2019-2020 | |
| Alcon Vision LLC | $24.34 | 2024 | Simbrinza |
| Abbvie INC. | $23.97 | 2025 | |
| Bausch & Lomb Americas INC. | $21.88 | 2025 | Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $18.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.80 | 2019 | |
| Alimera Sciences, INC. | $16.59 | 2024 | Yutiq, Iluvien |
| Smith+Nephew, INC. | $15.78 | 2023 | Coblation |
| Amgen INC. | $15.44 | 2025 | Tepezza |
| Merck Sharp & Dohme LLC | $15.19 | 2023 | |
| Forte Bio-Pharma LLC | $6.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.